Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
World game at war: why some European nations have threatened a World Cup boycott 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
AUSTIN, Texas, May 03, 2018 -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its first quarter ended March 31, 2018 financial results on Monday, May 14, 2018, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.
| Monday, May 14th @ 4:30pm Eastern Time | |||
| Domestic: | 800-239-9838 | ||
| International: | 323-794-2551 | ||
| Conference ID: | 5200441 | ||
| Webcast: | http://public.viavid.com/index.php?id=129615 | ||
| Replays, Available through May 28: | |||
| Domestic: | 844-512-2921 | ||
| International: | 412-317-6671 | ||
| Replay PIN: | 5200441 | ||
About Vermillion
Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. Vermillion, Inc.’s tests are intended to characterize and stage disease, and to help guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in monitoring response to therapy.
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-535-7742
[email protected]
